These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24041347)

  • 21. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
    Brogan AJ; Talbird SE; Thompson JR; Miller JD; Rubin J; Deniz B
    PLoS One; 2014; 9(3):e90295. PubMed ID: 24603445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
    Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
    Sulkowski MS; Poordad F; Manns MP; Bronowicki JP; Rajender Reddy K; Harrison SA; Afdhal NH; Sings HL; Pedicone LD; Koury KJ; Sniukiene V; Burroughs MH; Albrecht JK; Brass CA; Jacobson IM;
    Hepatology; 2013 Mar; 57(3):974-84. PubMed ID: 23081753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Goodman ZD; Sings HL; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R;
    N Engl J Med; 2011 Mar; 364(13):1207-17. PubMed ID: 21449784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
    Vellopoulou A; van Agthoven M; van der Kolk A; de Knegt RJ; Berdeaux G; Cure S; Bianic F; Lamotte M
    Appl Health Econ Health Policy; 2014 Dec; 12(6):647-59. PubMed ID: 25103219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boceprevir for untreated chronic HCV genotype 1 infection.
    Poordad F; McCone J; Bacon BR; Bruno S; Manns MP; Sulkowski MS; Jacobson IM; Reddy KR; Goodman ZD; Boparai N; DiNubile MJ; Sniukiene V; Brass CA; Albrecht JK; Bronowicki JP;
    N Engl J Med; 2011 Mar; 364(13):1195-206. PubMed ID: 21449783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
    Garnock-Jones KP
    Drugs; 2012 Dec; 72(18):2431-56. PubMed ID: 23231027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
    Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.
    Gordon SC; Yoshida EM; Lawitz EJ; Bacon BR; Sulkowski MS; Davis M; Poordad F; Bronowicki JP; Esteban R; Sniukiene V; Burroughs MH; Deng W; Dutko FJ; Brass CA; Albrecht JK; Rajender Reddy K
    Aliment Pharmacol Ther; 2013 Jul; 38(1):16-27. PubMed ID: 23710734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
    Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
    Taieb V; Pacou M; Ho S; Pettré S; Van Sanden S; Pisini M; Ustianowski A; Mehnert A
    J Med Econ; 2015; 18(10):787-96. PubMed ID: 25934147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.
    McEwan P; Kim R; Yuan Y
    Appl Health Econ Health Policy; 2013 Feb; 11(1):53-63. PubMed ID: 23329380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Craxì A; Cammà C;
    Hepatology; 2014 May; 59(5):1692-705. PubMed ID: 24691835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.